FAQ on Intelligent Bio Solutions Inc.'s FDA 510(k) Submission Enhancement

What is the Intelligent Fingerprinting Drug Screening System?

The Intelligent Fingerprinting Drug Screening System is a non-invasive, rapid testing solution that uses fingerprint sweat analysis to screen for recent drug use, targeting substances like opiates, cocaine, methamphetamine, and cannabis.

Why is the new cybersecurity and performance data important for INBS?

The new data validates the system’s resilience and accuracy through rigorous testing, supporting INBS’s FDA 510(k) resubmission and paving the way for U.S. market entry.

How does the Intelligent Fingerprinting Drug Screening System work?

It collects fingerprint sweat samples in seconds and delivers results in under ten minutes, offering a hygienic and cost-effective method for drug screening.

When does INBS plan to submit its updated findings to the FDA?

INBS aims to submit its updated findings in August, with the goal of entering the U.S. market by 2025.

Who are the current customer segments for INBS outside the U.S.?

Current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

What are the potential broader applications of the Intelligent Fingerprinting Drug Screening System?

Beyond workplace drug screening, the technology has potential for broader applications in additional fields, though specific fields are not mentioned in the content.

How can investors stay updated on INBS news?

Investors can find the latest news and updates in the company’s newsroom at https://ibn.fm/INBS.

What makes the Intelligent Fingerprinting Drug Screening System unique compared to alternatives?

Its non-invasive nature, rapid results, and use of fingerprint sweat analysis for drug screening distinguish it from traditional methods, offering a hygienic and cost-effective solution.